Associations between statins and COPD: A systematic review

被引：66

作者：

Dobler C.C. ^{[1
,2
]}

Wong K.K. ^{[1
]}

Marks G.B. ^{[1
,2
,3
]}

机构：

[1] Woolcock Institute of Medical Research, Sydney, NSW

[2] Department of Respiratory Medicine, Liverpool Hospital, Sydney, NSW

[3] South Western Sydney Clinical School, University of New South Wales, Sydney, NSW

来源：

BMC Pulmonary Medicine | / 9卷 / 1期

关键词：

Chronic Obstructive Pulmonary Disease; Simvastatin; Atorvastatin; Pravastatin; Chronic Obstructive Pulmonary Disease Patient;

D O I：

10.1186/1471-2466-9-32

中图分类号：

学科分类号：

摘要：

Background: Statins have anti-inflammatory and immunomodulating properties which could possibly influence inflammatory airways disease. We assessed evidence for disease modifying effects of statin treatment in patients with chronic obstructive pulmonary disease (COPD). Methods: A systematic review was conducted of studies which reported effects of statin treatment in COPD. Data sources searched included MEDLINE, EMBASE and reference lists. Results: Eight papers reporting nine original studies met the selection criteria. One was a randomized controlled trial (RCT), one a retrospective nested case-control study, five were retrospective cohort studies of which one was linked with a case-control study, and one was a retrospective population-based analysis. Outcomes associated with treatment with statins included decreased all-cause mortality in three out of four studies (OR/HR 0.48-0.67 in three studies, OR 0.99 in one study), decreased COPD-related mortality (OR 0.19-0.29), reduction in incidence of respiratory-related urgent care (OR 0.74), fewer COPD exacerbations (OR 0.43), fewer intubations for COPD exacerbations (OR 0.1) and attenuated decline in pulmonary function. The RCT reported improvement in exercise capacity and dyspnea after exercise associated with decreased levels of C-reactive protein and Interleukin-6 in statin users, but no improvement of lung function. Conclusion: There is evidence from observational studies and one RCT that statins may reduce morbidity and/or mortality in COPD patients. Further interventional studies are required to confirm these findings. © 2009 Dobler et al; licensee BioMed Central Ltd.

引用

共 39 条

[1]

Murray C.L., Alternative visions of the future: Projecting mortality and disability, The Global Burden of Disease, pp. 361-375, (1996)

[2]

Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connett J.E., The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial, Ann Intern Med, 142, pp. 233-239, (2005)

[3]

Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema, Lancet, 1, pp. 681-686, (1981)

[4]

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial, Ann Intern Med, 93, pp. 391-398, (1980)

[5]

Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., Mosca L., Pasternak R.C., Pearson T., Pfeffer M.A., Taubert K.A., AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute, Circulation, 113, pp. 2363-2372, (2006)

[6]

Barnes P.J., Shapiro S.D., Pauwels R.A., Chronic obstructive pulmonary disease: Molecular and cellular mechanisms, Eur Respir J, 22, pp. 672-688, (2003)

[7]

Gan W.Q., Man S.F., Senthilselvan A., Sin D.D., Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis, Thorax, 59, pp. 574-580, (2004)

[8]

Lee J.H., Lee D.S., Kim E.K., Choe K.H., Oh Y.M., Shim T.S., Kim S.E., Lee Y.S., Lee S.D., Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs, Am J Respir Crit Care Med, 172, pp. 987-993, (2005)

[9]

Palinski W., New evidence for beneficial effects of statins unrelated to lipid lowering, Arterioscler Thromb Vasc Biol, 21, pp. 3-5, (2001)

[10]

Davignon J., Leiter L.A., Ongoing clinical trials of the pleiotropic effects of statins, Vasc Health Risk Manag, 1, pp. 29-40, (2005)

← 1 2 3 4 →